Catalent expands OptiMelt hot melt extrusion capabilities4 Apr 2019
The investment includes the addition of equipment to enhance development capabilities for preclinical and early clinical phase development, as well as adding downstream processing technologies to support HME formulations.
Catalent Pharma Solutions has invested a further $5 million at the company’s Somerset, New Jersey, drug development center of excellence to expand its OptiMelt hot melt extrusion (HME) capabilities.
As a technology, HME offers several advantages, including development of amorphous dispersions and controlled and modified drug delivery to enhance a drug’s bioavailability, as well as taste masking of bitter APIs. The investment will include the addition of a number of pieces of manufacturing and analytical equipment to enhance development capabilities for preclinical and early clinical phase development, as well as adding downstream processing technologies to support HME formulations.
“The developmental challenges to overcome issues with drug solubility and bioavailability are well documented, and our OptiMelt HME technology is one of many potential solutions that Catalent has to offer,” commented Jonathan Arnold, President of Oral Drug Delivery at Catalent. “Our strategy is to work with drug innovators to optimize the formulation and delivery method of a drug, and HME enables us to develop more patient-centric dose forms, including controlled release.”
In 2018, Catalent announced an investment in the Somerset facility to create a new drug development center of excellence, which, alongside sites in San Diego, California and Nottingham, UK, offer formulation and development services focused on preclinical to clinical Phase IIb formulation, analytical, and manufacturing solutions for orally delivered small molecules.
Catalent’s 265,000-sq ft headquarters and development center in Somerset has a long track record of successfully developing, launching, and manufacturing many oral treatments for leading global innovators. The site houses state-of-the-art analytical labs, pilot and clinical scale equipment including hot melt extrusion and fluid-bed processing and has significant expertise in handling potent and US Drug Enforcement Administration (DEA) compounds for capsules, tablets, minitablets and multi-particulates.
Isotype-specific secondary antibodies for improved signal detection
10 Apr 2019
Offer an alternative to cross-adsorbed secondary antibodies when absolute specificity is required.Read more
Sterling Pharma to acquire CiVentiChem in the US
9 Apr 2019
The acquisition will enhance the CDMO's chemistry development capabilities to support pre-clinical and early phase clinical supply.Read more
'Drugs from bugs' joint venture
4 Apr 2019
Lonza and Chr. Hansen create a strategic joint venture to become the partner of choice for developing and manufacturing live biotherapeutic products for pharma and biotech customers.Read more
Curcumin and pomegrantes - new hope for Alzheimer’s prevention?
3 Apr 2019
New research at University of Warwick will test how curcumin kick-starts the brain’s cleansing of damaging plaques and cells.Read more
MedPharm's appointment with Destiny
28 Mar 2019
Global contract provider to develop new XF-platform drug formulations for the treatment of a number of topically treated infections, including diabetic foot ulcers and ophthalmic infections.Read more
Third Sartorius Research Xchange Forum 2019 focuses on CAR-T cell therapy
13 Mar 2019
Event for experts from academia and industry, including talks, live demo sessions, and panel discussion.Read more
Envigo launches PATHWAY to enable FIH clinical trials
11 Mar 2019
PATHWAY manages the complexity of the entire safety assessment process on behalf of the company’s pharmaceutical and biotechnology customers.Read more
Biogen acquisition boosts its ophthalmology pipeline
4 Mar 2019
Nightstar Therapeutics has two potentially first-in-class mid- to late-stage clinical assets as well as preclinical programs.Read more
Uniqsis expands LED photoreactor range
3 Mar 2019
The availability of three new alternative switchable LED configurations provides chemists with the unique ability to optimally undertake almost any photochemistry reaction.Read more
Crowdfund and discover promising therapeutics via Molecule
21 Feb 2019
Connecting scientists, patients, and industry to advance drug development in a collaborative open market.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation